GA
LGND icon

Geneva Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

Geneva Advisors’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$1.95M Buy
25,691
+673
+3% +$47.1K 0.03% 225
2017
Q1 		$1.65M Buy
25,018
+1,058
+4% +$69.6K 0.03% 250
2016
Q4 		$1.52M Buy
23,960
+1,359
+6% +$85.8K 0.03% 257
2016
Q3 		$1.44M Buy
22,601
+6,964
+45% +$511K 0.03% 249
2016
Q2 		$1.16M Buy
15,637
+1,345
+9% +$99.8K 0.02% 282
2016
Q1 		$955K Buy
+14,292
New +$869K 0.02% 304

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
SCM
Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Geneva Advisors's LGND Position: Q2 2017 in Review

Geneva Advisors increased its Ligand Pharmaceuticals (LGND) stake by 2.7% in Q2 2017, buying an estimated $47.1K and bringing the position to 25,691 shares worth $1.95M. The position accounts for 0.03% of the portfolio, ranked #225.

Geneva Advisors first reported a position in LGND in Q1 2016 and has held it in 6 quarters since. 266 funds tracked by Wall St. Rank hold LGND as of Q2 2017.

  • Geneva Advisors held 25,691 shares of Ligand Pharmaceuticals worth $1.95M as of Q2 2017.
  • Geneva Advisors bought 673 Ligand Pharmaceuticals shares in Q2 2017, an estimated $47.1K.
  • Ligand Pharmaceuticals made up 0.03% of Geneva Advisors's portfolio in Q2 2017, its #225 holding.
  • Geneva Advisors first reported a position in Ligand Pharmaceuticals in Q1 2016 and has held it in 6 quarters since.
  • 266 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2017.

Based on Geneva Advisors's 13F filing for Q2 2017, filed 7 Aug 2017.